DPIIT recognised startup Government of India
Startup India
Immunoadoptive Cell Therapy Private Limited - healthcare in Thane, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2026
₹77.75 Cr
▲ 15% YoY
Net loss · FY 2026
₹1.84 Cr
Net margin -2.4%
EBITDA · FY 2026
₹3.52 Cr
EBITDA margin 4.5%
Authorised capital
₹49 Lakh
Registered with MCA
Paid-up capital
₹2.01 Lakh
Issued & subscribed
Company age
8 yrs
Est. 2018
Employees · EPFO
69
Provident fund records
Directors on board
6
As per MCA filings
About Immunoadoptive Cell Therapy Private Limited
Data last updated:
Immunoadoptive Cell Therapy Private Limited is a private limited company based in Thane, Maharashtra, India, recognised as a startup by DPIIT. It operates in the preventive healthcare segment of the healthcare sector. It was incorporated on 08 October 2018 and has been in existence for over 8 years.
Its director C Satyanarayana is #163 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2018PTC315497. Its GSTIN is 27AAFCI0254E1ZX (Maharashtra). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹49 Lakh and a paid-up capital of ₹2.01 Lakh. It is led by directors including Shalini Rahul Purwar (Whole-Time Director) and Rahul Purwar.
Its last annual general meeting (AGM) was held on 25 June 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Thane, Maharashtra.
As per the financials filed for FY 2026, the company reported a revenue of ₹77.75 Cr, a growth of 15% compared to the previous year. For the same year it recorded a net loss of ₹1.84 Cr (net margin -2.4%) and EBITDA of ₹3.52 Cr (EBITDA margin 4.5%). Revenue has grown at a compounded annual rate (CAGR) of 378% over three years and 406% over five years.
The company has about 69 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: ImmunoACT. The company has 12 deals on record (7 secondary share transfers, 5 funding rounds), with disclosed funding of ₹133.27 Cr; the latest was in March 2024. The company has 2 MSME Form 1 returns on record between 2022 and 2023, listing 30 overdue payments to 14 micro and small suppliers.
Immunoadoptive Cell Therapy Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-MH-33-0168408). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website immunoact.com.
Company details
CIN U74999MH2018PTC315497
Registration Number 315497
Incorporation Date 08 October 2018
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 25 June 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
MSME Classification MSME
Udyam Registration UDYAM-MH-33-0168408
Key People
Shalini Rahul Purwar Whole-Time Director Rahul Purwar Director Satyanarayana Chava Nominee Director Recognitions & Rankings of Immunoadoptive Cell Therapy
MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-MH-33-0168408
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #163 C Satyanarayana ₹22,900 Cr
Contact details
Immunoadoptive Cell Therapy Private Limited's registered office is in Thane, Maharashtra. Its website is immunoact.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.D – 222/26 Ttc Industrial Area, MIDC Village Shiravane Navi Mumbai, Thane, Maharashtra, India – 400706
- IndustryHealthcare, Preventive Health Services
To see the full contact details of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Comprehensive company report
Immunoadoptive Cell Therapy Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Immunoadoptive Cell Therapy operates one associated brand: ImmunoACT. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Cell therapies for cancer treatment are developed. | immunoact.com |
Business activity
The main business activity of Immunoadoptive Cell Therapy is professional, scientific and technical activities. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, scientific and technical activities | 72 | Scientific research and development |
To see the full business activity and turnover split of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Financials of Immunoadoptive Cell Therapy Private Limited
FY 2026 filings availableImmunoadoptive Cell Therapy Private Limited reported revenue of ₹77.75 Cr (up 15% YoY) for FY 2026.
Revenue · FY 2026
₹77.75 Cr ▲ 15%
Net loss · FY 2026
₹1.84 Cr margin -2.4%
EBITDA · FY 2026
₹3.52 Cr margin 4.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 15%
3 years · compounded
▲ 378%
5 years · compounded
▲ 406%
EBITDA CAGR growth
1 year
▼ 71%
Revenue has grown at a compounded annual rate (CAGR) of 406% over five years, including 15% growth in the latest year. EBITDA fell 71% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹77.75 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.52 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹1.84 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.5% | ||||
| Net Profit Margin | -2.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Board of directors of Immunoadoptive Cell Therapy Private Limited
Immunoadoptive Cell Therapy has 6 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rahul Purwar Also directs: Immunoact Research Foundation, Advy Biosciences Private Limited | Director | 08 Oct 2018 | 8 Years 1 Months | Current |
| Shalini Rahul Purwar Also directs: Immunoact Research Foundation | Whole-Time Director | 08 Oct 2018 | 8 Years 1 Months | Current |
| Satyanarayana Chava Also directs: Laurus Labs Limited, Laurus Bio Private Limited, Krka Pharma Private Limited and 1 more | Nominee Director | 09 Dec 2021 | 4 Years 11 Months | Current |
| Ravindranath Kancherla Also directs: Hygieia Global Health Services LLP, Laurus Labs Limited, Arunachalam Automotives Private Limited and 5 more | Nominee Director | 09 Dec 2021 | 4 Years 11 Months | Current |
| Shirish Arya Also directs: Immunoact Research Foundation | Director | 06 Aug 2021 | 5 Years 3 Months | Current |
| Atharva Ajay Karulkar | Director | 29 Oct 2021 | 5 Years 0 Months | Current |
Auditor
Immunoadoptive Cell Therapy Private Limited is audited by Deloitte Haskins & Sells for the financial year 2026.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells | FY 2026 | 008072S |
Shareholding
The shareholding of Immunoadoptive Cell Therapy Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Deals & funding
Immunoadoptive Cell Therapy Private Limited has 12 deals on record (7 secondary share transfers, 5 funding rounds), with disclosed funding of ₹133.27 Cr; the latest was in March 2024.
Total deals
12
Secondary share transfers
7
Funding rounds
5
Disclosed funding
₹133.27 Cr
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Nov 2023 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Oct 2023 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Jul 2023 | Funding round · Series B | ₹80.02 Cr | Investors: Laurus Labs Limited |
| Dec 2021 | Funding round · Series A | ₹52.8 Cr | Investors: Laurus Labs Limited , Nsn Investments, Leven Holdings |
To see the full deal history of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Immunoadoptive Cell Therapy Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Immunoadoptive Cell Therapy Private Limited has 2 MSME Form 1 returns on record between 2022 and 2023, listing 30 overdue payments to 14 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 14)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Shree Maruti Integrated Logistics Private Limited | |||
| Sunny Sterile Products | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Immunoadoptive Cell Therapy Private Limited has a workforce of 69 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
Employee count
69
Active EPFO establishments
1
Employee growth
155.56%
GST
Immunoadoptive Cell Therapy has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAFCI0254E1ZX | Maharashtra | Active | 11 Apr 2019 |
To see the full GST registrations and return filing status of Immunoadoptive Cell Therapy Private Limited, buy the company report.
Recent activity
Immunoadoptive Cell Therapy Private Limited has 11 board changes on record since 2018: 6 appointments and 5 cessations. The latest: Shalini Rahul Purwar ceased to be Director on 21 Jul 2024.
AGM
Immunoadoptive Cell Therapy Private Limited last Annual general meeting of members was held on 25 Jun 2026 as per latest MCA records.
Filing
Immunoadoptive Cell Therapy Private Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Ceased
Shalini Rahul Purwar ceased to be Director.
Ceased
Rahul Purwar ceased to be Director.
Appointed
Ravindranath Kancherla was appointed as Nominee Director.
Appointed
Satyanarayana Chava was appointed as Nominee Director.
Ceased
Atharva Ajay Karulkar ceased to be Additional Director.
Ceased
Shirish Arya ceased to be Additional Director.
Appointed
Atharva Ajay Karulkar was appointed as Director.
Ceased
Alka Dwivedi ceased to be Director.
Appointed
Shirish Arya was appointed as Director.
Appointed
Rahul Purwar was appointed as Director.
2 earlier events are in the company report.
News
From our blog
Frequently asked questions
Immunoadoptive Cell Therapy is an active private limited company based in Thane, Maharashtra, India. The company works in preventive health services, within the healthcare industry. It was incorporated on 08 October 2018 (8+ years old) and is registered under CIN U74999MH2018PTC315497.
Immunoadoptive Cell Therapy has 6 current directors:
- Shalini Rahul Purwar - Whole-Time Director
- Rahul Purwar - Director
- Satyanarayana Chava - Nominee Director
- Ravindranath Kancherla - Nominee Director
- Shirish Arya - Director
- Atharva Ajay Karulkar - Director
The latest financial statements of Immunoadoptive Cell Therapy on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 June 2026. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Immunoadoptive Cell Therapy is 27AAFCI0254E1ZX, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Immunoadoptive Cell Therapy is U74999MH2018PTC315497. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Immunoadoptive Cell Therapy was incorporated on 08 October 2018, making it 8+ years old. It is registered with the Registrar of Companies, Mumbai.
Immunoadoptive Cell Therapy has 12 deals on record (7 secondary share transfers, 5 funding rounds), with disclosed funding of ₹133.27 Cr; the latest was in March 2024.
Shalini Rahul Purwar ceased to be Director on 21 Jul 2024. Rahul Purwar ceased to be Director on 12 Feb 2024. Ravindranath Kancherla was appointed as Nominee Director on 09 Dec 2021. Immunoadoptive Cell Therapy has 11 board changes on record in total.
Yes, Immunoadoptive Cell Therapy is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Yes, Immunoadoptive Cell Therapy is registered as an MSME under Udyam registration (number: UDYAM-MH-33-0168408).
Immunoadoptive Cell Therapy has 2 MSME Form 1 returns on record between 2022 and 2023, listing 30 overdue payments to 14 micro and small suppliers. The latest return was filed on 05 Dec 2023.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages